Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 20, 2019

Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial

Merck KGaA and Pfizer have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (stage III or stage IV).

Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial